Compare Eli Lilly And Co (LLY) vs Trade Desk Inc (TTD) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

The Trade Desk (TTD) trades at $18.68, down 76% year-to-date amid slowing revenue growth and executive turnover. Recent technical signals are bearish, with moving averages indicating selling pressure, while fundamentals show strong profitability with a 77.83% gross margin and 14.57% net margin. The company has beaten earnings estimates in two of the last three quarters but missed Q1 2026 expectations. Recent news highlights key executive appointments and a resolved dispute with Publicis Groupe.

Outlook: TTD faces headwinds from competitive pressure and growth deceleration, but current valuation at 21.13x P/E may attract value investors. Risks include market share loss to larger rivals and execution challenges. Analyst consensus price target of $25.23 suggests 35% upside potential, though sentiment remains divided with nearly equal buy and hold ratings.